In the absence of a submission from the holder of the marketing authorisation, delamanid (Deltyba®) cannot be endorsed for use within NHS Wales for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.